Neoplasms × Sarcoma × Clear all
NCT06910657 2026-03-02

IDOV-Immune for Advanced Solid Tumors

ViroMissile, Inc.

Phase 1 Recruiting
78 enrolled
NCT07410676 2026-02-18

EBNK-ST-001

Essen Biotech

Phase 1/2 Recruiting
83 enrolled
NCT03911388 2026-02-17

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

M.D. Anderson Cancer Center

Phase 1 Recruiting
24 enrolled
NCT04260802 2026-01-12

A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

Ocellaris Pharma, Inc.

Phase 1/2 Terminated
73 enrolled
NCT03899792 2026-01-06

LIBRETTO-121

Eli Lilly and Company

Phase 1/2 Active not recruiting
36 enrolled 13 charts 2 FDA
NCT06171945 2025-10-27

AYAConnect

UNC Lineberger Comprehensive Cancer Center

Phase NA Completed
63 enrolled
NCT01552434 2025-10-14

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
155 enrolled
NCT03162536 2025-09-08

ARQ 531-101

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1/2 Active not recruiting
190 enrolled
NCT06582849 2025-08-26

EARN

Washington University School of Medicine

Phase NA Completed
33 enrolled
NCT03093116 2025-07-10

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 2 FDA